2023
AMH predicts miscarriage in non-PCOS but not in PCOS related infertility ART cycles
Arkfeld C, Han E, Tal R, Seifer D. AMH predicts miscarriage in non-PCOS but not in PCOS related infertility ART cycles. Reproductive Biology And Endocrinology 2023, 21: 35. PMID: 37020210, PMCID: PMC10074664, DOI: 10.1186/s12958-023-01087-5.Peer-Reviewed Original ResearchConceptsBody mass indexMiscarriage rateMean AMHART cyclesNumber of embryosElevated AMHAMH valuesOdds ratioNon-PCOS patientsOverall miscarriage rateConfidence intervalsAutologous embryo transferSART CORS databaseMultivariate regression analysisHeterotopic pregnancyClinical pregnancyAMH levelsIVF cyclesPCOS patientsPCOS populationIndependent predictorsMass indexPatient populationOocyte bankingAutologous transferAMH independently predicts aneuploidy but not live birth per transfer in IVF PGT-A cycles
Li H, Seifer D, Tal R. AMH independently predicts aneuploidy but not live birth per transfer in IVF PGT-A cycles. Reproductive Biology And Endocrinology 2023, 21: 19. PMID: 36739415, PMCID: PMC9898926, DOI: 10.1186/s12958-023-01066-w.Peer-Reviewed Original ResearchConceptsAnti-Müllerian hormoneNumber of embryosEuploid embryosLive birthsOocyte qualityAge groupsSignificant independent predictorsCase-control analysisSART CORS databasePreimplantation genetic testingAMH levelsIVF cyclesIndependent predictorsIVF outcomesOocyte yieldNormal embryosPredictive roleGenetic testingFinal analysisBirthAgeIVFSubset of cyclesHormonePGT
2022
Anti-Mullerian Hormone Signaling: Relevance for Pathophysiology of PCOS and Implications for Novel Therapeutic Approaches to Managing Ovulatory Dysfunction of PCOS
Shapiro A, Kushnir V, Seifer D. Anti-Mullerian Hormone Signaling: Relevance for Pathophysiology of PCOS and Implications for Novel Therapeutic Approaches to Managing Ovulatory Dysfunction of PCOS. 2022, 511-525. DOI: 10.1007/978-3-030-92589-5_25.Peer-Reviewed Original ResearchPolycystic ovary syndromeAnti-Mullerian hormonePathophysiology of PCOSSerum anti-Mullerian hormoneElevated AMH levelsAvailable treatment modalitiesNovel therapeutic approachesFuture therapeutic targetsChronic anovulationOvulatory dysfunctionAMH levelsOvary syndromeOvulatory functionTreatment modalitiesNormal folliculogenesisTherapeutic approachesTherapeutic targetPatientsCritical roleAnovulationDysfunctionPathophysiologySyndromeFolliculogenesisHormone
2021
Ethnicity/Race and Age-Specific Variations of Serum AMH in Women—A Review
Kotlyar AM, Seifer DB. Ethnicity/Race and Age-Specific Variations of Serum AMH in Women—A Review. Frontiers In Endocrinology 2021, 11: 593216. PMID: 33633682, PMCID: PMC7900163, DOI: 10.3389/fendo.2020.593216.Peer-Reviewed Original Research
2020
Anti-Müllerian hormone as a qualitative marker - or just quantity?
Kotlyar A, Seifer DB. Anti-Müllerian hormone as a qualitative marker - or just quantity? Current Opinion In Obstetrics & Gynecology 2020, 32: 219-226. PMID: 32205525, DOI: 10.1097/gco.0000000000000623.Peer-Reviewed Original ResearchConceptsAnti-Müllerian hormoneOvarian reserve testingClinical pregnancy rateLive birth rateOnset of menopausePremature ovarian insufficiencyNumber of oocytesSignificant predictive valueAMH levelsFertilization cyclesPregnancy rateOvarian insufficiencyIntracycle variabilityOocyte qualityPredictive valueEarly folliclesFetal trisomiesHormoneReproductive technologiesRiskQualitative markersSmall interMenopauseInsufficiencyFolliclesHigh serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology
Tal R, Seifer CM, Khanimov M, Seifer DB, Tal O. High serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology. Reproductive Biology And Endocrinology 2020, 18: 20. PMID: 32156287, PMCID: PMC7065318, DOI: 10.1186/s12958-020-00581-4.Peer-Reviewed Original ResearchConceptsLive birth rateLower live birth ratesHigh AMH groupAMH groupPCOS womenHigh AMHAMH concentrationsFirst fresh IVF/ICSI cycleBirth rateFresh IVF/ICSI cyclesGreater clinical pregnancy ratesSerum antimullerian hormone (AMH) levelsIVF/ICSI cyclesAntimullerian hormone levelsClinical pregnancy rateControlled ovarian stimulationRetrospective cohort studySerum AMH levelsPolycystic ovarian syndromeSerum AMH concentrationsLive birth outcomesNumber of embryosAMH levelsGonadotropin doseOvarian stimulation
2015
Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimüllerian hormone: a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012–2013
Seifer DB, Tal O, Wantman E, Edul P, Baker VL. Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimüllerian hormone: a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012–2013. Fertility And Sterility 2015, 105: 385-393.e3. PMID: 26515380, DOI: 10.1016/j.fertnstert.2015.10.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersCryopreservationDatabases, FactualEmbryo TransferFemaleFertilityFertilization in VitroHumansInfertilityLinear ModelsLive BirthLogistic ModelsMiddle AgedMultivariate AnalysisOocyte RetrievalPatient SelectionPregnancyPregnancy RatePregnancy, MultipleReproductive Techniques, AssistedRetrospective StudiesRisk AssessmentRisk FactorsTreatment OutcomeYoung AdultConceptsLive birth rateAntimüllerian hormoneCancellation rateAMH levelsAssisted Reproductive Technology Clinic Outcome Reporting System databaseAssisted reproduction technology (ART) outcomesEmbryo cryopreservation ratesSerum antimüllerian hormoneTotal cancellation rateMultiple birth ratesReporting System databaseCycle startAutologous cyclesClinical pregnancyCycle cancellationPrognostic factorsAMH valuesFresh cyclesCycle outcomePrognostic indicatorAMH concentrationsRetrospective analysisMAIN OUTCOMEEmbryo transferMultivariate analysisAssessing ovarian response: antral follicle count versus anti-Müllerian hormone
Fleming R, Seifer DB, Frattarelli JL, Ruman J. Assessing ovarian response: antral follicle count versus anti-Müllerian hormone. Reproductive BioMedicine Online 2015, 31: 486-496. PMID: 26283017, DOI: 10.1016/j.rbmo.2015.06.015.Peer-Reviewed Original ResearchConceptsAntral follicle countAnti-Müllerian hormoneAMH levelsOvarian reserveFollicle countOvarian responseFollicle numberPredictive valueSerum anti-Müllerian hormoneGood predictive valuePersonalization of treatmentGold standard biomarkerOvarian stimulationExogenous gonadotrophinsMenstrual cyclePoor responseHormone biomarkersOocyte numberUltrasound biomarkersBiomarkersAmerican SocietyGood responseSame ageHormoneStimulation
2014
Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis
Tal R, Tal O, Seifer BJ, Seifer DB. Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertility And Sterility 2014, 103: 119-130.e3. PMID: 25450298, DOI: 10.1016/j.fertnstert.2014.09.041.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEmbryo ImplantationFemaleFertilization in VitroHumansInfertility, FemaleMiddle AgedObservational Studies as TopicOvarian ReserveOvaryOvulation InductionPregnancyPregnancy OutcomePregnancy RatePrevalenceReproducibility of ResultsRisk FactorsSensitivity and SpecificityYoung AdultConceptsPredictor of implantationClinical pregnancy rateAntimüllerian hormoneClinical pregnancyOvarian reservePregnancy rateOdds ratioIVF/intracytoplasmic sperm injectionSystematic reviewSerum AMH levelsPolycystic ovary syndromeReproductive technologiesIntracytoplasmic sperm injectionNondonor cyclesAMH levelsOvary syndromeImplantation rateDiagnostic odds ratioObservational studyMAIN OUTCOMEClinical utilitySperm injectionPregnancyAssisted conceptionFertility treatmentImpact of CD4+ Lymphocytes and HIV Infection on Anti‐Müllerian Hormone Levels in a Large Cohort of HIV‐infected and HIV‐uninfected Women
Scherzer R, Bacchetti P, Messerlian G, Goderre J, Maki PM, Seifer DB, Anastos K, Karim R, Greenblatt RM. Impact of CD4+ Lymphocytes and HIV Infection on Anti‐Müllerian Hormone Levels in a Large Cohort of HIV‐infected and HIV‐uninfected Women. American Journal Of Reproductive Immunology 2014, 73: 273-284. PMID: 25339186, PMCID: PMC4323676, DOI: 10.1111/aji.12332.Peer-Reviewed Original ResearchConceptsAnti-Müllerian hormone levelsUninfected womenHigh AMHHIV infectionCD4 countLymphocyte countHormone levelsCurrent CD4 countImpact of CD4Total lymphocyte countCD4 T cellsHormonal contraceptive useOvarian granulosa cell functionsGranulosa cell functionPast weight lossHIV viraemiaNadir CD4Undetectable viraemiaUninfected participantsAMH levelsLow AMHOvarian functionDetectable viraemiaT cellsLarge cohortCharacterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes
Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. American Journal Of Obstetrics And Gynecology 2014, 211: 59.e1-59.e8. PMID: 24593938, DOI: 10.1016/j.ajog.2014.02.026.Peer-Reviewed Original ResearchConceptsSerum antimüllerian hormone levelsAntimüllerian hormone levelsClinical pregnancy ratePopulation of womenAMH levelsPregnancy rateHormone levelsHigher clinical pregnancy rateElevated AMH levelsPresence of amenorrheaMultiple pregnancy rateOvarian hyperstimulation syndromeRetrospective cohort studyHigher AMH levelsPolycystic ovarian morphologyPolycystic ovarian syndromeSyndrome phenotypeReproductive technology outcomesHyperstimulation syndromePCOS severityClinical pregnancyOvarian stimulationTotal testosteroneCohort studyOvarian syndromeVitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS
Irani M, Minkoff H, Seifer DB, Merhi Z. Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS. The Journal Of Clinical Endocrinology & Metabolism 2014, 99: e886-e890. PMID: 24606102, DOI: 10.1210/jc.2013-4374.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsPolycystic ovary syndromeAnti-Mullerian hormoneSerum anti-Mullerian hormoneGlycation end productsVitamin DSerum sRAGED3 supplementationDeficient womenAMH concentrationsVit D3Soluble receptorDeposition of AGEsAbnormal ovarian folliculogenesisDihydroxyvitamin D3 supplementationSerum sRAGE levelsVit D3 supplementationVitamin D supplementationSerum AMH levelsVitamin D deficiencyBody mass indexD supplementationAMH levelsD deficiencySRAGE levels
2013
Potential Mechanisms for Racial and Ethnic Differences in Antimüllerian Hormone and Ovarian Reserve
Tal R, Seifer DB. Potential Mechanisms for Racial and Ethnic Differences in Antimüllerian Hormone and Ovarian Reserve. International Journal Of Endocrinology 2013, 2013: 818912. PMID: 24348557, PMCID: PMC3857838, DOI: 10.1155/2013/818912.Peer-Reviewed Original ResearchOvarian reserveAntimüllerian hormoneRacial differencesSerum antimüllerian hormoneSerum AMH levelsVitamin D deficiencyReproductive technology treatmentEthnic differencesImportant clinical implicationsSuch racial differencesAMH levelsD deficiencyInfertility treatmentTreatment outcomesReproductive endocrinologistsReproductive planningEthnic groupsTimely interventionClinical implicationsReproductive agingSensitive biomarkerTechnology treatmentEthnic variationGenetic factorsPotential mechanismsVitamin D supplementation appears to normalize serum AMH levels in vitamin D deficient premenopausal women
Irani M, Seifer D, Minkoff H, Merhi Z. Vitamin D supplementation appears to normalize serum AMH levels in vitamin D deficient premenopausal women. Fertility And Sterility 2013, 100: s338. DOI: 10.1016/j.fertnstert.2013.07.892.Peer-Reviewed Original Research
2011
Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with normal ovarian reserve
Buyuk E, Seifer DB, Illions E, Grazi RV, Lieman H. Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with normal ovarian reserve. Fertility And Sterility 2011, 95: 2364-2368. PMID: 21529798, DOI: 10.1016/j.fertnstert.2011.03.081.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersBody Mass IndexCross-Sectional StudiesDown-RegulationFemaleFollicle Stimulating Hormone, HumanHumansInfertility, FemaleLinear ModelsNew YorkOocyte RetrievalOverweightOvulationOvulation InductionReproductive Techniques, AssistedRisk AssessmentRisk FactorsConceptsElevated body mass indexNormal ovarian reserveBody mass indexSerum AMH levelsOvarian reserveNumber of oocytesAMH levelsObese womenInfertile womenMass indexHormone levelsDay 3 serum FSH levelsSerum anti-Mullerian hormone (AMH) levelsAnti-Mullerian hormone levelsLow serum AMH levelsSerum antimullerian hormone (AMH) levelsNormal body mass indexAntimullerian hormone levelsReproductive technology cyclesSerum FSH levelsDiminished ovarian reserveIU/L.Cross-sectional studyOvarian hyperstimulationIVF cyclesRandom anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels
Buyuk E, Seifer DB, Younger J, Grazi RV, Lieman H. Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels. Fertility And Sterility 2011, 95: 2369-2372. PMID: 21497340, DOI: 10.1016/j.fertnstert.2011.03.071.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersChi-Square DistributionEmbryo TransferFemaleFertilization in VitroFollicle Stimulating Hormone, HumanFollicular PhaseHumansInfertility, FemaleNew YorkOocyte RetrievalOvulationOvulation InductionPregnancyPregnancy RateRetrospective StudiesTime FactorsTreatment OutcomeUp-RegulationConceptsAnti-Müllerian hormoneNumber of oocytesClinical pregnancy rateSerum AMH levelsDiminished ovarian reserveAMH levelsFSH levelsDay 3 embryosElevated FSHOvarian responseART cyclesPregnancy rateEarly follicular FSH levelsFollicle-stimulating hormone levelsSerum anti-Müllerian hormoneCycle cancellation rateSerum FSH levelsReproductive technology programCycle cancellationOvarian reserveRetrospective studyHormone levelsMAIN OUTCOMECancellation rateRandom sera
2010
Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States
Seifer DB, Baker VL, Leader B. Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertility And Sterility 2010, 95: 747-750. PMID: 21074758, DOI: 10.1016/j.fertnstert.2010.10.011.Peer-Reviewed Original ResearchConceptsAnti-Müllerian hormone valuesAMH valuesHormone valuesAge 35Mean AMH valueSerum AMH valuesAverage yearly decreaseYears of ageU.S. fertility clinicsSpecific medianAMH levelsClinical reference laboratoryRetrospective studyFertility centerReproductive ageMAIN OUTCOMEAge 40Rate of declineFertility clinicsReference laboratoryWomenAgeReproductive optionsYearly decreaseSD values